References
- Daemen T., Veninga A., Roerdink F.H., Scherphof G.L. In vitro activation of liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide. Cancer Res. 1986; 46: 4330
- Phillips N.C., Rioux J.D., Tsao M. Activation of murine Kupffer cells tumoricidal activity by liposomes containing lipophylic muramyl dipeptide. Hepatol. 1988; 8: 1046
- Daemen T., Dontje B., Veninga A., Scherphof G.L., Oosterhuis W.L. Therapy of murine liver metastases by administration of MDP encapsulated in liposomes. Selective Cancer Ther. 1990; 6: 63
- Phillips N.C., Tsao M.S. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative. Cancer Res. 1989; 49: 936
- Dijkstra J., Van Galen W.J.M., Hulstaert C.E., Kalicharan D., Roerdink F.H., Scherphof G.L. Interaction of liposomes with Kupffer cells in vitro. Exp. Cell Res. 1984; 150: 161
- Daemen T., Veninga A., Regts J., Scherphof G.L. Maintenance of tumoricidal activity and susceptibility to reactivation of subpopulations of rat liver macrophages. J. Immunother. 1991; 10: 200
- Hoedemakers R.M.J., Daemen T., Scherphof G.L. Tumor-cytolytic activity and TNF secretion of the rat liver macrophage population after intravenous administration of liposome-encapsulated MDP. “Cells of the hepatic sinusoid.”, E. Wisse, D.L. Knook, R.S. McCuskey. Kuffer Cell Foundation, RijswijkThe Netherlands 1991; Vol 3: 319
- Wadler S., Schwartz E.L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 1990; 50: 3473
- Williams D.L., Sherwood E.R., McNamee R.B., Jones E.L., Browder I.W., Di Luzio N.R. Chemoimmunotherapy of experimental hepatic metastases. Hepatol. 1987; 7: 1296
- Daemen T., Regts J., Morselt H., Scherphof G.L. The effect of liver macrophages on in vitro cytolytic activity of 5FU and FUdR on colon carcinoma cells: evidence of macrophage activation. Int. J Immunopharmacol. 1992; 14: 857
- Mayer R.J., Maclntyre J.M., Steele G.D., Frei E. High-dose bolus 5-fluoruracil (5-FU) for metastatic colorectal carcinoma. Proc. Am. Soc. Clin. Oncol. 1983; 2: 127
- Gasparetto C., Laver J., Abboud M., Gillio A., Smith C., O'Reilly R., Moore M.A.S. Effects of Interleukin-1 on hematopoietic progenitors: Evidence of stimulatory and inhibitory activities in a primate model. Blood 1989; 74: 547
- Crown J., Jakubowski A., Kemeny N., Gordon M., Gasparetto C., Wong G., Sheridan C., Toner G., Meisenberg B., Botet J., Applewhite J., Sinha S., Moore M., Kelsen D., Buhles W., Gabrilove J. A phase I trial of recombinant human interleukin-lb alone and in combination with myelosuppressive closes of 5-fluorouracil in patients with gastrointestinal cancer. Blood 1991; 78: 1420
- Moore M.A.S., Warren D.J. Synergy of Interleukin-1 and granulocyte colony-stimulating factor: In vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc. Natl. Acad. Sci. U.S.A. 1987; 84: 7134